PMC_TTAC-0001_03 A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

NCT03856099

A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

Associated Conditions

Brain Cancer

Principal Investigator

Herbert Newton

Sponsor

PharmAbcine

The aim of this study is to assess the safety and effectiveness of the study drug, TTAC-0001 to patients with recurrent glioblastoma which has progressed on bevacizumab treatment. Another aim is to measure the levels of TTAC-0001 in the blood over time (called pharmacokinetic or PK testing). The study will also assess changes in the level of tumor biomarkers in the blood over time (called pharmacodynamic or PD testing).